- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04720729
Chemotherapy Monitoring by ctDNA in HER2- Metastatic Breast Cancer (MONDRIAN)
Chemotherapy Monitoring by Circulating Tumor DNA (ctDNA) in HER2 (Human Epidermal Growth Factor Receptor-2)- Metastatic Breast Cancer (MONDRIAN): a Phase 2 Study
This is a one-arm, single site, open-label phase II study. Patients will be enrolled in the screening step at the start of the second line of chemotherapy, and will undergo blood draws for ctDNA detection. Patients for whom ctDNA was successfully detected and found informative by the study executive board could then be included in the interventional step when starting a new line of therapy.
ctDNA will be quantified using the customized test, at baseline and day 15 (+/- 3 working day) of cycle #1, and results will be made available before the cycle 2 Day 1, together with a treatment management recommendation by the Study Executive Board (continuation or discontinuation of the corresponding chemotherapy)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients will be enrolled in the screening step at the start of the second line of chemotherapy, and will undergo blood draws for ctDNA detection:
That second line of treatment will be managed by clinical and radiological evaluations (RECIST); ctDNA will not be released to clinician and patient in real time.
While the included patient is being treated by second line therapy, a customized ctDNA detection based on tumor mutations (droplet-digital PCR) will be developed. Once set up, the two blood above-mentioned samples will be subjected to ctDNA detection. The SEB will then retrospectively assess whether ctDNA levels changes during the second line of treatment were indicative of the efficacy of the second line therapy. Patients for whom ctDNA was successfully detected and found informative by the SEB (Steering Executive Board) could then be included in the interventional step when starting a new line of therapy.
The third blood draw for ctDNA detection will be used to compare results to the tumor evaluation performed by imaging.
In the interventional step, ctDNA analyses and interpretation will be performed in real time; results made available before the cycle 2. Quantitative results will be interpreted by the laboratory committee, with two possible recommendations:
- ctDNA changes at day 15 display a major drop (Mutant Allelic Frequency (MAF) or copies/ml) reduced by 40% or more compared to baseline: continuing the same chemotherapy will be recommended;
- ctDNA changes at day 15 display no major drop (MAF or copies/ml) either increased, stable or reduced by less than 40% compared to baseline: changing chemotherapy will be recommended; In light of ctDNA levels changes observed during the second line for each included patient, the above-mentioned thresholds might be modified, on a case-by-case basis, by the SEB (to keep into account individual characteristics).
The test will be repeated for any new line of therapy that may be initiated during the first 6 months following the accrual of each patient in the interventional step. If this strategy is considered efficient (on an individual basis), further ctDNA tests will be made available on request for the next six months. Consequently, the patients who will change chemotherapy line after the recommendation following result from C1D15 ctDNA results will have a new ctDNA test at C1D1 and C1D15 of the new chemotherapy line.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Luc CABEL, MD
- Phone Number: +33 1 47 11 16 07
- Email: luc.cabel@curie.fr
Study Locations
-
-
-
Paris, France, 75005
- Recruiting
- Institut Curie
-
Contact:
- François-Clément BIDARD, PR
- Email: francois-clement.bidard@curie.fr
-
Contact:
- Luc CABEL, MD
- Email: luc.cabel@curie.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- Written informed consent
- Woman ≥ 18 years old
- Performance status 0-2
- Advanced HER2-negative metastatic breast cancer on the last tumor tissue assessed (ASCO-CAP (College of American Pathologists) guidelines)
- Eligible to a second line of chemotherapy for MBC (Metastatic Breast Cancer)
- Evaluable disease (per RECIST v1.1)
- Organ functions compatible with the use of chemotherapies (as decided by the investigator)
- No isolated CNS progression or leptomeningeal carcinomatosis
- No concurrent stage IV malignancy
- No concurrent severe and/or uncontrolled medical or psychological condition that would contraindicate participation in this study
Additional criteria for the screening step :
Presence of a known somatic mutation deemed trackable in circulating cell-free DNA. If the tumoral genetic landscape is unknown at inclusion, its characterization should be requested (or ongoing) at inclusion
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Single arm
Patients with HER2-negative metastatic breast cancer, starting a second line of chemotherapy
|
During the screening step (2nd chemotherapy line, cycle 1) : at each time point (L2C1D1 & L2C1D15), 30 ml of blood will be drawn on special tubes with conservative suited for ctDNA analyses (e.g. STRECK® tubes).Then cell-free circulating DNA (cfcDNA) will be extracted from plasma following the manufacturer recommendations. cfcDNA will be quantified, and minimum 500-1000 copies will be analyzed by droplet digital PCR (ddPCR). Analyses will define if ctDNA could be detected during L2. For the interventional step, from L3 (3rd chemotherapy line) : 20 ml of blood will be drawn at L3C1D1 and L3C1D15. If ctDNA at D15 shows a major drop (> 40%) from D1, treatment will be continued. If ctDNA at D15 shows no major drop from D1, chemotherapy will be changed. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
L3C1 : ctDNA quantification
Time Frame: At the Day 1 of Cycle 1 (each cycle is 21 days)
|
ctDNA quantification (Mutant Allelic Frequency (MAF) %) during 3rd chemotherapy Line, 1st cycle (L3C1)
|
At the Day 1 of Cycle 1 (each cycle is 21 days)
|
L3C1 : ctDNA quantification
Time Frame: At the Day 15 of Cycle 1 (each cycle is 21 days)
|
ctDNA quantification (Mutant Allelic Frequency (MAF) %) during 3rd chemotherapy Line, 1st cycle (L3C1)
|
At the Day 15 of Cycle 1 (each cycle is 21 days)
|
L3C1 : chemotherapy efficacy
Time Frame: ctDNA difference between Day 15 and Day 1
|
ctDNA change : if major drop from D1 to D15 (MAF>40%), no change on treatment.
If no major drop from D1 to D15, change of chemotherapy
|
ctDNA difference between Day 15 and Day 1
|
LxC1 : ctDNA quantification
Time Frame: At the Day 1 of the Cycle 1 (each cycle is 21 days)
|
ctDNA quantification (MAF %) during 4th chemotherapy line and following : Line x, 1st cycle (LxC1)
|
At the Day 1 of the Cycle 1 (each cycle is 21 days)
|
LxC1 : ctDNA quantification
Time Frame: At the Day 15 of the Cycle 1 (each cycle is 21 days)
|
ctDNA quantification (MAF %) during 4th chemotherapy line and following : Line x, 1st cycle (LxC1)
|
At the Day 15 of the Cycle 1 (each cycle is 21 days)
|
LxC1 : chemotherapy efficacy
Time Frame: ctDNA difference between Day 15 and Day 1
|
ctDNA change : if major drop from D1 to D15 (MAF>40%), no change on treatment recommanded If no major drop from D1 to D15, change of chemotherapy recommanded
|
ctDNA difference between Day 15 and Day 1
|
Progression Free Survival (PFS)
Time Frame: From date of inclusion until the date of first documented progression or date of death from any cause, whichever came first, assessed every 8-weeks up to 18 months
|
Tumor assessment (MRI and/or CT) by RECIST 1.1
|
From date of inclusion until the date of first documented progression or date of death from any cause, whichever came first, assessed every 8-weeks up to 18 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: François-Clément BIDARD, PR, INSTITUT CURIE - Medical Oncology
- Study Chair: Steven LE GOUILL, PR, MD, INSTITUT CURIE - Hospital
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IC 2020-10
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HER2-negative Metastatic Breast Cancer
-
QuantumLeap Healthcare CollaborativeRecruitingSolid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditionsUnited States
-
AIO-Studien-gGmbHNovartis Pharmaceuticals; iOMEDICO AGCompletedHer2-negative Metastatic Breast Cancer | Her2-negative Locally Advanced Breast CancerGermany
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
HutchmedActive, not recruitingRectal Cancer | Advanced Solid Tumors | Metastatic Breast Cancer | Triple Negative Breast Cancer | Metastatic Colon Cancer | Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedBreast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Hormone Receptor Negative Breast Cancer | HER2+ Breast CancerUnited States
-
SOLTI Breast Cancer Research GroupRecruitingMetastatic Breast Cancer | Triple Negative Breast Cancer | HER2-negative Breast CancerSpain
-
Prof. Wolfgang JanniEli Lilly and CompanyRecruitingHormone Receptor-positive Metastatic Breast Cancer | HER2-negative Metastatic Breast CancerGermany, Switzerland
-
National Cancer Institute (NCI)Active, not recruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Unresectable Breast Carcinoma | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma | Metastatic HER2-Negative Breast Carcinoma | Unresectable HER2-Negative Breast Carcinoma | Locally Advanced HER2-Negative...United States
Clinical Trials on Chemotherapy monitoring by circulating tumor DNA analysis
-
Centre Henri BecquerelRecruitingPrimary Mediastinal Large B-cell LymphomaFrance
-
Institut du Cancer de Montpellier - Val d'AurelleCompleted
-
Zealand University HospitalRecruitingNon-small Cell Lung Cancer MetastaticDenmark
-
Zhujiang HospitalNot yet recruitingRecurrence | Hepatocellular Carcinoma | Surgery | Circulating Tumor CellChina
-
Christer EricssonKarolinska Institutet; iCellate MedicalUnknownCancer | Neoplasms, Unknown PrimarySweden
-
Zhujiang HospitalRecruitingHepatocellular Carcinoma ResectableChina
-
Rigshospitalet, DenmarkRecruitingGastric Cancer | Esophageal CancerDenmark
-
Helsinki University Central HospitalInstitute for Molecular MedicineUnknown
-
Sunnybrook Health Sciences CentreMOUNT SINAI HOSPITAL; Princess Margaret Hospital, Canada; Trillium Health PartnersRecruiting
-
Fudan UniversityRecruiting